Is Your Chlorthalidone on the Recall List?
If your chlorthalidone bottle shows lot RISA24001, RISB24002, or RISA24002 with an April 2027 expiration, it is on the FDA recall list and should be swapped this week. Any other bottle is fine. The problem is that the tablets may not fully dissolve, so they can act weaker than the label says. Don't stop taking the pill while you sort this out, because interrupting blood pressure therapy is linked to a measured increase in stroke and heart attack risk.
The recall covers generic chlorthalidone 25 mg sent to pharmacies nationwide. It's split across two actions involving the same maker, Inventia Healthcare, and the same distributor, Rising Pharma. FDA testing found the tablets failed dissolution specifications. Both actions were classified Class II, which the FDA defines as temporary or medically reversible consequences with a remote chance of serious injury.
What went wrong with the pills
Dissolution testing checks whether a tablet releases its active ingredient at the expected rate once it hits stomach fluid. These bottles failed that check, so some patients taking them may have been getting a tablet that behaves like a lower dose than the label says. That is different from an adulterated or contaminated pill, and the recall does not cite any contamination.
The June 5, 2026 action is recall number D-0610-2026 and covers 11,460 bottles across two lots. The September 3, 2026 action is D-0852-2026 and covers another 13,567 bottles. Together that's 25,027 bottles of 25 mg tablets. No injuries tied to these lots have been publicly reported.
The 60-second bottle check
Pull the bottle. The label lists a lot number near the expiration date, and only three combinations are recalled.
| Lot number | Bottle size and NDC |
|---|---|
| RISA24001 | 100-count (NDC 64980-599-01) |
| RISB24002 | 1,000-count (NDC 64980-599-10) |
| RISA24002 | 100-count (NDC 64980-599-01) |
All three expire April 2027. If your bottle doesn't match one of those lot numbers and that expiration, it isn't part of the recall and there's nothing to do. If it does match, keep taking your dose on schedule and call your pharmacy today to arrange a replacement bottle or an equivalent diuretic chosen by your prescriber.
Why pausing is the wrong fix
The impulse to toss the bottle and wait is understandable, and it is also the one response with measurable harm attached. A meta-analysis of 27 million hypertensive patients found that missing doses was linked to systolic pressure about 3 to 4 mmHg higher and more than double the odds of uncontrolled blood pressure. In a large nationwide cohort, poor adherence was linked to a higher combined risk of death, heart attack, stroke, and heart failure hospitalization at every level of blood pressure.
The 2018 valsartan recall is the closest analog. Hypertensive patients still exposed to the recalled drug had about a 22% increase within six months in composite cardiac events (heart attacks, heart failure, strokes, and severe hypertension). Coverage across the population held up only because switching to alternatives surged. Within 90 days of the first recall, switch rates rose by about 8.5 percentage points, more than three times the baseline rate. People with Medicare or commercial insurance switched more often than those paying cash or on Medicaid fee-for-service.
What a same-week swap looks like
Chlorthalidone is a long-acting diuretic that has been studied for decades and is still a standard first-line blood pressure drug. In the pragmatic Diuretic Comparison Project in veterans, it tied hydrochlorothiazide for major cardiovascular events at the doses most people take. There are plenty of acceptable substitutes while your pharmacist sources an unaffected bottle.
Call the pharmacy that filled your prescription. Ask them to check your refill against the three recalled lot numbers and dispense a replacement from an unaffected lot, or, if the supply is tight, ask your prescriber about hydrochlorothiazide at an equivalent dose until the stock recovers. Keep taking your current dose on schedule in the meantime. If you also want a quick check that your pressure is holding during the switch, home cuff readings over a few days are the fastest signal, and a basic metabolic panel will show your potassium, which is the lab worth watching on any thiazide.
What would change this advice
Three things would change it. An FDA upgrade to Class I, which signals a reasonable probability of serious harm, would raise the stakes of staying on a recalled bottle. MedWatch reports of actual injuries tied to RISA24001, RISB24002, or RISA24002 would move the question from under-dosing to real harm. A national chlorthalidone shortage severe enough that neither a replacement nor an equivalent diuretic can be dispensed within a few days would turn the swap into a bridging conversation your prescriber needs to run. None of those is in play right now.